Practical Aspects of Risk Assessment in Gastrointestinal Stromal Tumors
Open Access
- 7 May 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Gastrointestinal Cancer
- Vol. 45 (3), 262-267
- https://doi.org/10.1007/s12029-014-9615-x
Abstract
Introduction: Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract, which are characterized in the majority of cases by activating mutations in KIT and platelet-derived growth factor receptor alpha (PDGFRA). The introduction of tyrosine kinase inhibitors has revolutionized the management of patients with metastatic GIST. However, complete surgical resection remains the mainstay of management for those with localized disease. Recently, three large trials have confirmed the benefit of adjuvant imatinib therapy in patients who were at high risk of recurrence following complete resection. In this setting, it is critical that oncologists understand the various GIST risk assessment criteria and be able to apply these methods to accurately assess the risk of recurrence and the need for adjuvant imatinib therapy. Purpose: The aim of this review is to outline the risk stratification systems currently available to oncologists who are treating patients with GIST, so they can be optimally applied for clinical decision-making.Keywords
This publication has 44 references indexed in Scilit:
- The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST)Clinical Sarcoma Research, 2012
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal TumorJAMA, 2012
- Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsThe Lancet Oncology, 2011
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysisThe Lancet Oncology, 2009
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialThe Lancet, 2009
- Risk stratification of patients diagnosed with gastrointestinal stromal tumorHuman Pathology, 2008
- Spectrum and prognostication of KIT and PDGFRA mutation in gastrointestinal stromal tumorsEuropean Journal of Surgical Oncology, 2008
- Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based studyBMC Cancer, 2007
- Factors Associated With Disease Progression in Patients With Gastrointestinal Stromal Tumors in the Pre-Imatinib EraAmerican Journal of Clinical Pathology, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005